LncRNA HCP5-encoded protein contributes to adriamycin resistance through ERK/mTOR pathway-mediated autophagy in breast cancer cells  

作　　者：Jia-Ni Xing Yi-Ni Shang Zheng-Ling Yu Shun-Heng Zhou Wang-Yang Chen Li-Hong Wang 

机构地区：[1]Department of Pathophysiology,Medical College of Southeast University,Nanjing,Jiangsu 210009,China [2]Department of Biomedical Engineering,Nanjing University of Aeronautics and Astronautics,Nanjing,Jiangsu 211106,China [3]School of Medicine,Taizhou University,Taizhou,Zhejiang 318000,China [4]Jiangsu Provincial Key Laboratory of Critical Care Medicine,Nanjing,Jiangsu 210009,China

出　　处：《Genes & Diseases》2024年第4期69-72,共4页基因与疾病（英文）

基　　金：funded by the National Natural Science Foundation of China(No.81972478);the Fundamental Research Funds for the Central Universities(China)(No.2242020K40131);the Jiangsu Provincial Key Laboratory of Critical Care Medicine(China)(No.JSKLCCM-2022-02-013).

摘　　要：Adriamycin(ADR),also known as doxorubicin,is an anthracycline anticancer drug and a chemotherapeutic drug commonly used in breast cancer treatments.1 However,breast cancer patients can gradually become tolerant to chemotherapy.Therefore,improving the curative effect of ADR remains an urgent problem to be solved.Autophagy is a complex catabolic process;normal living cells break down damaged organelles or aggregated molecules and absorb energy to maintain homeostasis through autophagy.

关 键 词：BREAST cancer HOMEOSTASIS 

分 类 号：R737.9[医药卫生—肿瘤]